Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series

Page 1

	Year	Citations
High Frequency of Mutations of the <i>PIK3CA</i> Gene in Human Cancers Yardena Samuels, Zhenghe Wang, Alberto Bardelli, Science EngineeringMonths470last 12Data ScienceData MiningMedicine	2004	3.4K
Determination of mean valproic acid serum level by assay of a single pooled sample Robert A. Hamilton, William R. Garnett, Berry J. Kline Clinical Pharmacology & Therapeutics	1981	250
PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity Jing Yuan, Pramod P. Mehta, Min-Jean Yin, Molecular Cancer Therapeutics Antitumor ActivityPten LossCancer BiologyTumor BiologySignaling Pathway	2011	159
Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design Hengmiao Cheng, Shubha Bagrodia, Simon Bailey, MedChemComm Drug TargetTumor BiologyDrug DesignAnti-cancer AgentCompound 1	2010	73
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511 Mark H. Norman, Kristin L. Andrews, Yunxin Bo, Journal of Medicinal Chemistry Chemoprevention StrategyMolecular BiologyClinical CandidatePharmacotherapyChemical Biology	2012	50
Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR Phuong Le, Hengmiao Cheng, Sacha Ninkovic, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryBiochemistryPotent InhibitorMedicine	2012	36

Page 1